Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3223
Debt
Debt-to-Equity RatioN/A
Current Ratio4.05
Quick Ratio3.80
Price-To-Earnings
Trailing P/E Ratio-1.35
Forward P/E Ratio36.40
P/E GrowthN/A
Sales & Book Value
Annual Sales$920,000.00
Price / Sales32.52
Cash FlowN/A
Price / CashN/A
Book Value($0.17) per share
Price / Book-10.71
Profitability
EPS (Most Recent Fiscal Year)($1.35)
Net Income$-16,790,000.00
Net Margins6.76%
Return on Equity20.71%
Return on Assets3.00%
Miscellaneous
Employees34
Outstanding Shares16,440,000
Market Cap$31.89 million
AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.16. The biopharmaceutical company earned $0.17 million during the quarter. AEterna Zentaris had a net margin of 6.76% and a return on equity of 20.71%. View AEterna Zentaris' Earnings History.
When is AEterna Zentaris' next earnings date?
What price target have analysts set for AEZS?
2 Wall Street analysts have issued twelve-month target prices for AEterna Zentaris' stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate AEterna Zentaris' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for AEterna Zentaris.
What is the consensus analysts' recommendation for AEterna Zentaris?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.
Who are some of AEterna Zentaris' key competitors?
Some companies that are related to AEterna Zentaris include Steadymed (STDY), Trevena (TRVN), Sol Gel Technologies (SLGL), VBI Vaccines (VBIV), Iterum Therapeutics (ITRM), Conatus Pharmaceuticals (CNAT), Recro Pharma (REPH), Catalyst Biosciences (CBIO), MOTIF BIO PLC/S (MTFB), Infinity Pharmaceuticals (INFI), Checkpoint Therapeutics (CKPT), Provention Bio (PRVB), Zynerba Pharmaceuticals (ZYNE), CTI BioPharma (CTIC) and NewLink Genetics (NLNK).
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Mr. Michael V. Ward, Pres & CEO (Age 61)
- Mr. James Clavijo, CFO & Sec. (Age 52)
- Mr. Paul Burroughs, Director of Communications
- Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
- Mr. Brian Garrison, Sr. VP of Global Commercial Operations
Has AEterna Zentaris been receiving favorable news coverage?
Media headlines about AEZS stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AEterna Zentaris earned a media and rumor sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.12 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for AEterna Zentaris.
How do I buy shares of AEterna Zentaris?
Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEZS stock can currently be purchased for approximately $1.82.
How big of a company is AEterna Zentaris?
AEterna Zentaris has a market capitalization of $31.89 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-16,790,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. AEterna Zentaris employs 34 workers across the globe.
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3223 or via email at [email protected]
MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
